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a  b  s  t  r  a  c  t
Objectives: Intravenous therapy is a complex procedure usually requiring the preparation of
the medication in the clinical area before administration to the patient. Breaches in aseptic
technique  may result in microbial contaminations of vials which is a potential cause of dif-
ferent  avoidable infections. We  aimed to investigate the prevalence and pattern of microbial
contamination  of single- and multiple-dose vials in the largest pulmonary teaching hospital
in  Iran.
Methods: In a period of 2 months, opened single- and multiple-dose vials from different
wards  were sampled by a pharmacist. The name of the medication, ward, labeling of the
vials,  the date of opening, and storing temperature were recorded for each vial. Remained
contents  of each vial were cultured using appropriate bacterial and fungal growth media.
Results: Microbial contamination was identiﬁed in 11 of 205 (5.36%) of vials. The highest
contamination  rate was 14.28% for vials used in interventional bronchoscopy unit. The most
frequent  contaminated medication was insulin. Gram-positive bacteria (81.82%) were  more
signiﬁcantly involved than gram-negative ones (9.09%) and fungi (9.09%), with the highest
frequency  for Staphylococcus epidermidis.
Conclusions: Our data demonstrate that repeated use of vials especially if basic sterilitymeasures  are disobeyed can cause microbial contamination of administered products to
the  patients. Infection preventionists are responsible to train health care workers regarding
aseptic  techniques and apply guidelines for aseptic handling of intravenous solutions.
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Introduction
Thirty to ﬁfty percent of hospitalize patients receive intra-
venous  therapy which requires the preparation and handling
of  the medicine before administration to the patient.1 Par-
enteral  medications are usually given out in single- and
multiple-dose vials (SDVs and MDVs). A SDV is a vial of liquid
medication intended for parenteral administration (injection
or  infusion) that is meant for use in a single patient for a single
case/procedure/injection.2 A MDV  is a vial of liquid medication
intended for parenteral administration (injection or infusion)
that  contains more  than one dose of medication. MDVs should
be  dedicated to a single patient whenever possible.3
The revised version of United States Pharmacopeia (USP)
Chapter  797 is a comprehensive document that describes
standards and procedures to minimize the risk of contam-
ination of compounded parenteral products. The chapter
includes evidence-based instructions for pharmacy design,
washing,  garbing, cleaning, quality assurance, and personnel
training  and evaluation designed to improve compound-
ing  practices in all pharmacies that compound parenteral
products.4 However, sterile compounding procedures vary
widely  across the countries. In our country the majority of the
reconstitution  of injectable drugs is carried out right before the
administration  to the patient by the nursing staff. Prevalence
of  bacterial contamination of SDVs which were used more
than  once has been reported 5.6% in one of Iranian hospitals.5
Fungal contamination of SDVs and microbial contamination of
vials  containing preservative were not examined in this report.
The  information regarding extrinsic microbial contamination
of  injectable drugs and potentially serious adverse events is
slight  in our country and still no measure has been taken
to  improve standards for intravenous therapy. We designed
this  study to understand the prevalence of contaminations of
intravenous  medications in our hospital and to design future
intervention which could be made by infection control staff to
prevent the contaminations of the injectable drugs.
Material  and  methods
Sample  taking
Injectable drugs were  prepared in a room with no special air-
conditioning  on the ward  or unit in which everybody even the
patient  accompanied person and cleaning staff could enter in
and out liberally. Using sterile technique, 3 mL  of the medica-
tion  was  withdrawn from opened SDVs and MDVs daily by a
pharmacist  without prior warning. Before sampling, the vials
were  shaken briskly, and the rubber was  swabbed with 70%
ethanol.  Name, potency and total volume of the vial, clinical
ward,  labeling or nonlabeling of the vials, the date and time of
opening,  storage condition, expiration date, and manufacturer
name  were  then recorded.Laboratory  diagnostic
Each sample was  tested using three methods. (1) 1 mL  was put
into  a tube containing 15 mL  thioglycolate broth and incubated 0 1 3;1 7(1):69–73
at  37 ◦C for 10 days. The broth was  visually examined every
day  and subcultured onto blood, chocolate and sabouraud dex-
trose  agar plates every other day within 10 days or any time
that  the appearance seemed turbid.5 (2) 1 mL  was centrifuged
(3000  rpm, 15 min), then the pellete was  inoculated into blood,
chocolate,  MacConkey’s and sabouraud dextrose agar. Two
ﬁrst  media were  evaluated after 48 h and the sabouraud dex-
trose  agar was evaluated after 18 days. (3) 1 mL  was  ﬁltered
using  0.45 m ﬁlters and the ﬁlters were placed onto blood
agar  plates. Plates were  incubated for 48 h at 37 ◦C and evalu-
ated  for bacterial growth. They were stored for fungal growth
for  18 days. The bacterial isolates were identiﬁed using Gram’s
staining  and standard biochemical methods.
Statistical  analysis
Descriptive statistics were used to detail the distribution of
contaminated  vials and the contaminating microorganism.
Due to the non-normal distribution of values, Mann–Whitney
test was used to determine the relation of vial contamination
and the date of opening of vial. The relation of type of vial and
contamination rate was evaluated using Fisher’s exact test. A
P value of less than 0.05 was considered as statistically signif-
icant.  Statistical analysis was  performed using SPSS version
16.0.
Results
A total of 205 vials (165 SDVs and 40 MDVs) were  tested from 18
wards  and units, with 29 medication types. Table 1 shows sam-
pled  medications from different wards/units. All vials were
being  used within their expiration period, and no vial had
expired.  No statistical difference was  observed between con-
tamination  rate and the number of days that the vials were
opened.  A total of 115 (56.10%) vials were kept at room tem-
perature,  the rest at 4 ◦C.
Bacterial  contamination was  identiﬁed in 11 of 205 (5.36%)
of  vials. Contamination rate for SDVs and MDVs were 4.85%
and  7.50% respectively. There was  no signiﬁcant difference in
the frequency of contamination of different type of vials. Con-
taminations  were found in three internal wards, emergency
ward,  Intensive Care Unit (ICU), transplant unit, and interven-
tional  bronchoscopy unit. The highest contamination rate was
14.28%  (2/14) for vials used for interventional bronchoscopy
unit and the lowest was  4.54% (1/22) for vials used for one of
the  internal wards which named as internal ward  3.
The  most frequent contaminated solution was insulin NPH
100  U/mL. No mixed contamination was detected in any of
vials.  Gram-positive and gram-negative bacteria were  involved
in  9 (81.82%) and 1 (9.09%) of contaminations, respectively.
Fungal contamination was detected in one sample (9.09%).
Therefore, gram-positive bacteria were more signiﬁcantly
involved (p < 0.05) in vial contaminations. Most commonly
identiﬁed microorganisms were part of the normal com-
mensally ﬂora with the highest frequency for Staphylococcus
epidermidis (4/11 or 36.36%). Table 2 shows the distribution of
contaminated  vials in different wards/units of the hospital
along  with the contaminating microorganism and the char-
acteristics  of the vials.
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Table 1 – Medication, name of ward/unit, and number of sampled vials.
Medication Ward/unit Respective number
of  sampled vials
Acetylcysteine 200 mg/10 mL Pediatric 1
Aminophyline 250 mg Emergency, tuberculosis ICU 1, 1
Atracurium 50 mg/5 mL Interventional bronchoscopy 1
Atropin 0.5 mg/mL Interventional bronchoscopy 1
Blood cardioplegia Operation room and anesthesiology 1
Bupivacaine 100 mg/20 mL Operation room and anesthesiology 3
Ceftazidim 2 g Emergency 1
Dextrose  5% Internal  (3), internal (9), emergency, surgical ICU 4, 3, 1, 1
Dextrose 3.33% + sodium chloride 0.3% Internal  (9), pediatric, emergency 1,  5, 2
Ganciclovir 500 mg Transplant 2
Heparin 5000 U/mL Internal (3), internal (4), internal (9), tuberculosis (5), pediatric,
oncology, emergency, surgical ICU, sleep, surgery
1,  1, 1, 1, 1, 1, 1, 1, 1, 2
Hydrocortisone 100 mg Tuberculosis ICU 1
Insulin  NPH 100 U/mL Internal (3), internal (4), internal (9), tuberculosis (5),
tuberculosis (6), oncology, CCU, emergency, surgical ICU, post
CCU, surgery, transplant
1,  1, 2, 2, 1, 1, 1, 2, 1, 1, 2, 1
Insulin regular 100 U/mL Internal (3), internal (4), internal (9), tuberculosis (5),
tuberculosis (6), oncology, CCU, emergency, surgical ICU,
tuberculosis ICU, medical ICU, operation room and
anesthesiology, surgery, transplant
4,  1, 2, 2, 2, 1, 1, 3, 1, 1, 1, 1, 3, 1
Ketamine hydrochloride 50 mg/mL Interventional bronchoscopy, operation room and
anesthesiology
2, 1
Lidocaine 2% Interventional bronchoscopy 1
Magnesium sulfate 20% Internal (3), internal (4), internal (9), tuberculosis (6),
emergency, surgical ICU, tuberculosis ICU, medical ICU,
operation room and anesthesiology
1,  1, 1, 1, 2, 7, 1, 1, 1
Meropenem 1 g Surgical ICU 2
Methylprednisolone 500 mg Internal (9), pediatric, emergency 1, 2, 3
Morphine Internal (3) 1
Omnipaque 240 mg/mL Radiology 1
Potassium chloride 15% Internal (4), internal (9), tuberculosis (5), tuberculosis (6),
emergency, surgical ICU, tuberculosis ICU, medical ICU,
Operation room and anesthesiology, transplant
1,  3, 2, 1, 1, 9, 2, 6, 1, 3
Propofol 1% (w/v) Interventional bronchoscopy 1
Sodium  chloride 0.45% Emergency 1
Sodium chloride 5% Internal (3), emergency, tuberculosis ICU, medical ICU 2, 1, 1, 1
Sodium chloride 0.9%
Internal  (3), internal (4), internal (9), tuberculosis (5),
tuberculosis (6), pediatric, oncology, CCU, emergency, heart
clinic, surgical ICU, surgery, transplant
8,  6, 5, 1, 3, 5, 2, 3, 2, 1, 2, 10, 1
Succinylcholine 500 mg Interventional bronchoscopy 5














TNG 100 mg/mL Interventional bronchosc
Six (54.54%) of contaminated vials were not marked with
atient’s  name, which indicated that they were probably used
or  more  than one patient.
iscussion
ur data show a contamination rate of 5.36% with bacteria
nd  fungi, in the content of the SDVs and MDVs used in dif-
erent  wards/units of a pulmonary teaching hospital in Iran.
n  principle, preparation, storage and transportation of Com-
ounded  Sterile Preparations (CSPs) require aseptic conditions
nd  trained personnel. USP Chapter 797 is a comprehensive
ocument that describes standards and procedures to mini-
ize  the risk contamination of CSPs.6 But standards for CSPs
n  developing countries may  be limited by lack of resources1
(trained personnel and facilities). Non-standard preparation
and  handling of vials (which are assumed to be sterile) result
in  contamination rates, ranging from 0% to 27%.7
SDVs are preservative free vials which are intended to be
used  only once. Puncturing SDVs multiple times and pooling
preservative free solutions may  cause the potential contami-
nation  risk, possibly leading to severe infections in patients.8,9
In the current study 165 of 205 vials (80.49%) were  SDVs that
were  used as multiple-dose vials. This ﬁnding is more  than
reported  percentage of 50% in the literature.10,11
On the other hand MDVs contain antibacterial preserva-
tives and may  be used more  than once when preparation
and storage is according to the manufacturer’s recom-
mendations. (e.g., insulin, some heparin, lignocaine and
octeotride  products).8 If MDVs  must be used for more  than
one  patient, they should not be kept or accessed in the
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Table 2 – Distribution and frequency of contaminated vials in different wards/units, isolated bacteria, and the










Internal (3) 1/22 (4.54%) Candida sp. Insulin regular 100 U/mL 11 4–6 ◦C
Internal (4) 1/11 (9,09%) Micrococcus sp. Magnesium sulfate 20% 0 Room
temperature
Internal (9) 1/19  (5.26%) Micrococcus sp. Insulin  NPH 100 U/mL 16 4–6 ◦C
Transplant 1/8 (12.5%) Bacillus sp. Potassium  chloride 15% 33 Room
temperature
Interventional bronchoscopy 2/14  (14.28%) S. epidermidis Succinylcholine 500 mg 7 4–6 ◦C
S. epidermidis Succinylcholine 500 mg 8 4–6 ◦C
Emergency 2/21 (9.52%) S. epidermidis Methylprednisolone 500 mg 2  Room
temperature




Surgical ICU 3/24 (12.5%) Micrococcus sp. Potassium chloride 15% 0 Room
temperature
Nocardia sp. Sodium chloride 0.9% 2 Room
oliE. c
immediate patient treatment area. This is to prevent inad-
vertent  contamination of the vial through direct or indirect
contact  with potentially contaminated surfaces or equip-
ment  that could then lead to infections in next patients.
If  a MDVs  enters the immediate patient treatment area, it
should  be dedicated to that patient only and discarded after
use.3
It must be noticed that a preservative does not prevent
non-bacterial and non-fungal contaminations (e.g., viral, pro-
tozoa,  and prion pathogens) and does not prevent growth
of  microorganisms in low temperature.7 MDVs  remain prone
to  bacterial contamination and the use of them has been
reported to be a potential source of infections in differ-
ent  studies.12–17 Our study also shows that microorganisms
can survive in the presence of a preservative as 3 of the
contaminated vials were insulin. The sterility of multidose
insulin vials was  determined up to 50 days by Rathod
et  al. They showed bacterial contaminations in 8 of 69
insulin  vials and concluded that antibacterial preservatives
were  more  effective at room temperature than at refriger-
ator  temperature.18 Other study by Jackson et al. veriﬁed
that preﬁlled insulin syringes remained sterile for up to
one  month after preparation when they were prepared
using good aseptic technique and stored in the patient’s
refrigerator.19
The sterility of a CSP is directly related to employment
of the best practice and quality standards. Safe preparation
and  handling of CPSs within a properly operating unidirec-
tional  airﬂow in an ISO class 5 clean room in accordance with
USP  chapter 797 requirements is the best way  to avoid bac-
terial  or fungal contamination.20,21 The standardization then
the  centralization of the preparations and reconstitution of
CPSs  by infection prevention and control experts makes it
possible  to reduce contamination risk related to injectable
drugs.22 Although the requirements of USP chapter 797
may  appear complicated, expensive, and even unattainabletemperature
Insulin  NPH 100 U/mL 9 4–6 ◦C
in  developing countries, the ﬁrst step to establish qual-
ity  standards could be made through training of health
care  workers according to recommendations from CDC and
WHO.23,24 The most applied recommendations include dating
MDVs  after opening and discarding them on the manufac-
ture’s  dates, discarding SDVs after opening, and emphasizing
the  need for proper aseptic technique. Simple aseptic tech-
niques  that could be implemented in each hospital setting
may  be summarizes as: performing hand hygiene before
preparing medications for administration; using gloves, face
mask,  and avoidance of talking during an injection;25 wip-
ing  the outsides of vials with 70% isopropyl alcohol swabs
before  opening and aspirating the contents of vials using
a  5 p.m. ﬁlter straw26; and considering practical guidelines
for lipid based emulsions that supports bacterial growth
such  as propofol.27 Moreover reconstitution of high risk level
intravenous treatments by a centralized hospital pharmacy
service  under sterile conditions is the next measure to reduce
both  infection risk and cost due to discarding expensive
vials.
In  conclusion infection preventionists in develop-
ing countries should improve sterile compounding of
injectable products in a hospital. Although implemen-
tation of the guidelines from professional pharmacy
organizations, such as the American Society of Health-
System Pharmacists (ASHP) and the National Association
of  Boards of Pharmacy (NABP) guarantees patient
safety, understanding the problems and limitations in
a  hospital is essential to develop a regional standard
procedure.Conﬂict  of  interest
There is no conﬂict of interest that should be disclosed by the
authors.
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